PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Profound Medical Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.86−0.15 (-2.50%)
Close on Oct 19, 2026
- Market cap
- $213.01M
- P/E (TTM)
- 4.2
- Dividend yield
- –
Profound Medical statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Profound Medical | Industry median |
|---|---|---|
| Market Cap | $214.08M | $229.23M |
| Enterprise Value | $180.32M | $194.73M |
| PS Ratio | 11.22 | 3.14 |
| PB Ratio | 4.30 | 3.19 |
| P/TBV Ratio | 4.31 | 4.69 |
Enterprise value
| Measure | Profound Medical | Industry median |
|---|---|---|
| EV / Sales | 9.45 | 2.93 |
Income (trailing twelve months)
| Measure | Profound Medical | Industry median |
|---|---|---|
| Revenue | $19.09M | $102.39M |
| Gross Profit | $13.70M | $60.36M |
| Operating Income | -$35.37M | -$4.31M |
| Pretax Income | -$32.52M | -$2.26M |
| Net Income | -$32.75M | -$6.57M |
| EBITDA | -$35.37M | -$1.98M |
Margins
| Measure | Profound Medical | Industry median |
|---|---|---|
| Gross Margin | 71.8% | 55.1% |
| Operating Margin | -185.3% | -6.04% |
| Pretax Margin | -170.4% | -4.11% |
| Profit Margin | -171.6% | -10.5% |
| EBITDA Margin | -185.3% | -2.67% |
Returns
| Measure | Profound Medical | Industry median |
|---|---|---|
| Return on Equity (ROE) | -73.5% | -19.2% |
| Return on Assets (ROA) | -58.4% | -13.3% |
| Return on Invested Capital (ROIC) | -227.4% | -4.11% |
| Return on Capital Employed (ROCE) | -66.4% | -9.07% |
Growth
| Measure | Profound Medical | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 61.2% | 8.85% |
| Revenue Growth (3Y CAGR) | 34.1% | 7.08% |
| Revenue Growth (5Y CAGR) | 17.1% | 11.8% |
| EPS Growth (3Y CAGR) | 0.72% | 3.06% |
| EPS Growth (5Y CAGR) | 2.44% | 7.64% |
Balance sheet
| Measure | Profound Medical | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $38.27M | $37.33M |
| Total Debt | $4.51M | $72.66M |
| Net Cash (Debt) | $33.76M | $3.92M |
| Net Cash Per Share | $0.92 | $0.28 |
| Equity (Book Value) | $49.81M | $57.36M |
| Book Value Per Share | $1.36 | $2.81 |
| Tangible Book Value | $49.69M | $10.71M |
| Working Capital | $49.75M | $54.64M |
Financial position
| Measure | Profound Medical | Industry median |
|---|---|---|
| Current Ratio | 6.46 | 2.50 |
| Quick Ratio | 4.20 | 1.54 |
| Debt / Equity | 0.09 | 0.38 |
| Interest Coverage | -97.44 | -1.81 |
Cash flow (trailing twelve months)
| Measure | Profound Medical | Industry median |
|---|---|---|
| Operating Cash Flow | -$36.10M | -$653.46K |
Efficiency
| Measure | Profound Medical | Industry median |
|---|---|---|
| Asset Turnover | 0.34 | 0.59 |
| Inventory Turnover | 0.57 | 2.21 |
| Revenue Per Employee | $117.82K | $322.75K |
| Profits Per Employee | -$202.13K | -$52.11K |
| Employee Count | 162 | 197 |
Dividends and yields
| Measure | Profound Medical | Industry median |
|---|---|---|
| Earnings Yield | -15.3% | -6.92% |
Shares
| Measure | Profound Medical | Industry median |
|---|---|---|
| Shares Outstanding | 36,532,600 | 44,856,700 |
| Shares Change (YoY) | 20.8% | 3.35% |
| Shares Change (QoQ) | 0.54% | 0.27% |
| Float | 35,945,500 | 36,934,400 |
| Shares Held by Insiders | 1.61% | 10.6% |
| Shares Held by Institutions | 45.2% | 63.5% |
Taxes
| Measure | Profound Medical | Industry median |
|---|---|---|
| Income Tax | $227.00K | $1.52M |
Scores
| Measure | Profound Medical | Industry median |
|---|---|---|
| Altman Z-Score | 2.78 | 1.95 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from Profound Medical's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.